A nurse assesses a patient for the classic signs of acute inflammation.
Which signs and symptoms would the nurse observe in a patient experiencing acute inflammation?

Choice A rationale

The trough level, typically drawn just before the next dose, measures the lowest concentration of the drug in the bloodstream. An elevated trough indicates drug accumulation and risk of toxicity. The peak level, measured at the highest concentration, is generally not needed after an elevated trough, and a repeat peak would not address the immediate concern of potential toxicity.

Choice B rationale

Increasing the dose of the medication would lead to an even higher trough level and peak level, significantly elevating the risk of drug toxicity, as the current dose is already causing accumulation (evidenced by the high trough). Therapeutic drug monitoring (TDM) is used to prevent toxicity and maintain efficacy; therefore, a higher dose is contraindicated.

Choice C rationale

An elevated trough serum level (normal range varies by drug, but often <2 mcg/mL for vancomycin) signifies that the drug is being eliminated too slowly or the interval between doses is too short, leading to accumulation and an increased risk of toxicity. Reducing the dose or lengthening the dosing interval is the priority action to bring the trough level back into the therapeutic range and prevent organ damage.

Choice D rationale

Many medications, especially renally-excreted ones, have levels affected by kidney function. While obtaining a creatinine level (normal range ∼0.6-1.2 mg/dL) or estimated Glomerular Filtration Rate (eGFR) is important for assessing drug clearance and adjusting future dosing, the priority immediate intervention is to modify the existing dose regimen to prevent acute toxicity from the current high level.

Choice A rationale

Allopurinol is a xanthine oxidase inhibitor used for the long-term prophylaxis (prevention) of gout flares by decreasing the production of uric acid, thereby lowering serum uric acid levels. It is not the drug of choice for treating an acute, painful flare-up because it does not rapidly reduce the inflammation caused by existing urate crystal deposition in the joint.

Choice B rationale

Colchicine is an alkaloid used to treat acute gout flares by disrupting microtubule formation, which inhibits the migration of neutrophils to the site of inflammation and interferes with the inflammatory response triggered by urate crystals. It is most effective when administered within 24 hours of the onset of symptoms to reduce pain and inflammation rapidly.

Choice C rationale

Probenecid is a uricosuric agent that works by inhibiting the reabsorption of uric acid in the proximal renal tubules, thereby increasing the excretion of uric acid in the urine. Like allopurinol, it is used for the long-term management of gout in patients who underexcrete uric acid, but it is ineffective for rapid relief during an acute flare.

Choice D rationale

Sulfinpyrazone is another uricosuric agent, similar to probenecid, that promotes the excretion of uric acid through the kidneys. It is indicated for the prophylactic treatment of chronic gout to maintain low serum uric acid levels and prevent recurrent attacks. It is not an appropriate medication for the immediate, symptomatic relief required during an acute gout flare.